Octa-Arginine mediated delivery of wild-type Lnk protein inhibits TPO-induced M-MOK Megakaryoblastic leukemic cell growth by promoting apoptosis

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Looi, Chung Yeng ^a   Imanishi, Miki ^b   Takaki, Satoshi ^c   Sato, Miki ^a   Chiba, Natsuko ^d   Sasahara, Yoji ^a   Futaki, Shiroh ^b   Tsuchiya, Shigeru ^a   Kumaki, Satoru ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^d TOHOKU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ADAPTOR PROTEIN; ARGININE; ERYTHROPOIETIN; JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PROTEIN LNK; STAT PROTEIN; STEM CELL FACTOR; TG 101348; THROMBOPOIETIN; UNCLASSIFIED DRUG; FLAVONOID; HYBRID PROTEIN; LNK PROTEIN, HUMAN; MUTANT PROTEIN; OCTAARGININE; OLIGOPEPTIDE; PROTEIN; PYRROLIDINE DERIVATIVE; SULFONAMIDE; TG101348;

ACUTE MEGAKARYOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER GROWTH; CD34 SELECTION; CELL CYCLE ARREST; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MEGAKARYOPOIESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; WILD TYPE; ANIMAL; CELL CYCLE; CELL STRAIN COS1; CERCOPITHECUS; DRUG EFFECT; ENZYME ACTIVATION; ENZYMOLOGY; GENE TRANSFER; METABOLISM; PATHOLOGY; PROTEIN BINDING; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CERCOPITHECUS AETHIOPS; COS CELLS; ENZYME ACTIVATION; FLAVONOIDS; GENE TRANSFER TECHNIQUES; HUMANS; JANUS KINASE 2; LEUKEMIA, MEGAKARYOBLASTIC, ACUTE; MITOGEN-ACTIVATED PROTEIN KINASES; MUTANT PROTEINS; OLIGOPEPTIDES; PROTEIN BINDING; PROTEINS; PYRROLIDINES; RECOMBINANT FUSION PROTEINS; STAT TRANSCRIPTION FACTORS; SULFONAMIDES; THROMBOPOIETIN;

EID: 80051531340     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0023640     Document Type: Article

References (48)

1. Kaushansky K, (1995) Thrombopoietin: the primary regulator of platelet production. Blood 86: 419-431.
2. Kaushansky K, Lok S, Holly RD, Broudy VC, Lin N, et al. (1994) Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature 369: 568-571.
3. Wendling F, Vainchenker W, (1998) Thrombopoietin and its receptor. Eur Cytokine Netw 9: 221-231.
4. Feener EP, Rosario F, Dunn SL, Stancheva Z, Myers MG Jr, (2004) Tyrosine phosphorylation of Jak2 in the JH2 domain inhibits cytokine signaling. Mol Cell Biol 24: 4968-4978.
5. Sasaki A, Yasukawa H, Shouda T, Kitamura T, Dikic I, et al. (2000) CIS3/SOCS-3 suppresses erythropoietin (EPO) signaling by binding the EPO receptor and JAK2. J Biol Chem 275: 29338-29347.
6. Tong W, Zhang J, Lodish HF, (2005) Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways. Blood 105: 4604-4612.
7. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, et al. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434: 1144-1148.
8. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, et al. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352: 1779-1790.
9. Gueller S, Gery S, Nowak V, Liu L, Serve H, et al. (2008) Adaptor protein Lnk associates with Tyr(568) in c-Kit. Biochem J 415: 241-245.
10. Tong W, Lodish HF, (2004) Lnk inhibits Tpo-mpl signaling and Tpo-mediated megakaryocytopoiesis. J Exp Med 200: 569-580.
11. Simon C, Dondi E, Chaix A, de Sepulveda P, Kubiseski TJ, et al. (2008) Lnk adaptor protein down-regulates specific Kit-induced signaling pathways in primary mast cells. Blood 112: 4039-4047.
12. Gery S, Cao Q, Gueller S, Xing H, Tefferi A, et al. (2009) Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F. J Leukoc Biol 85: 957-965.
13. Gery S, Gueller S, Chumakova K, Kawamata N, Liu L, et al. (2007) Adaptor protein Lnk negatively regulates the mutant MPL, MPLW515L associated with myeloproliferative disorders. Blood 110: 3360-3364.
14. Takaki S, Morita H, Tezuka Y, Takatsu K, (2002) Enhanced hematopoiesis by hematopoietic progenitor cells lacking intracellular adaptor protein, Lnk. J Exp Med 195: 151-160.
15. Takaki S, Sauer K, Iritani BM, Chien S, Ebihara Y, et al. (2000) Control of B cell production by the adaptor protein lnk. Definition of a conserved family of signal-modulating proteins. Immunity 13: 599-609.
16. Takaki S, Tezuka Y, Sauer K, Kubo C, Kwon SM, et al. (2003) Impaired lymphopoiesis and altered B cell subpopulations in mice overexpressing Lnk adaptor protein. J Immunol 170: 703-710.
17. Velazquez L, Cheng AM, Fleming HE, Furlonger C, Vesely S, et al. (2002) Cytokine signaling and hematopoietic homeostasis are disrupted in Lnk-deficient mice. J Exp Med 195: 1599-1611.
18. Joliot A, Prochiantz A, (2005) [Transduction peptides, the useful face of a new signaling mechanism]. Med Sci (Paris) 21: 309-314.
19. Takenobu T, Tomizawa K, Matsushita M, Li ST, Moriwaki A, et al. (2002) Development of p53 protein transduction therapy using membrane-permeable peptides and the application to oral cancer cells. Mol Cancer Ther 1: 1043-1049.
20. Zhou H, Wu S, Joo JY, Zhu S, Han DW, et al. (2009) Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell 4: 381-384.
21. Zhou Y, Du W, Koretsky T, Bagby GC, Pang Q, (2008) TAT-mediated intracellular delivery of NPM-derived peptide induces apoptosis in leukemic cells and suppresses leukemogenesis in mice. Blood 112: 2474-2483.
22. Chikh GG, Kong S, Bally MB, Meunier JC, Schutze-Redelmeier MP, (2001) Efficient delivery of Antennapedia homeodomain fused to CTL epitope with liposomes into dendritic cells results in the activation of CD8+ T cells. J Immunol 167: 6462-6470.
23. Ford KG, Souberbielle BE, Darling D, Farzaneh F, (2001) Protein transduction: an alternative to genetic intervention? Gene Ther 8: 1-4.
24. Wender PA, Mitchell DJ, Pattabiraman K, Pelkey ET, Steinman L, et al. (2000) The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc Natl Acad Sci U S A 97: 13003-13008.
25. Futaki S, Suzuki T, Ohashi W, Yagami T, Tanaka S, et al. (2001) Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J Biol Chem 276: 5836-5840.
26. Noguchi H, Matsushita M, Okitsu T, Moriwaki A, Tomizawa K, et al. (2004) A new cell-permeable peptide allows successful allogeneic islet transplantation in mice. Nat Med 10: 305-309.
27. Bersenev A, Wu C, Balcerek J, Tong W, (2008) Lnk controls mouse hematopoietic stem cell self-renewal and quiescence through direct interactions with JAK2. J Clin Invest 118: 2832-2844.
28. Gery S, Gueller S, Nowak V, Sohn J, Hofmann WK, et al. (2009) Expression of the adaptor protein Lnk in leukemia cells. Exp Hematol 37: 585-592 e582.
29. Takenaka Y, Fukumori T, Yoshii T, Oka N, Inohara H, et al. (2004) Nuclear export of phosphorylated galectin-3 regulates its antiapoptotic activity in response to chemotherapeutic drugs. Mol Cell Biol 24: 4395-4406.
30. Itano M, Tsuchiya S, Minegishi N, Fujie H, Minegishi M, et al. (1995) Establishment and characterization of a novel human immature megakaryoblastic leukemia cell line, M-MOK, dependent on fibroblasts for its viability. Exp Hematol 23: 1301-1309.
31. Drexler HG, Zaborski M, Quentmeier H, (1997) Thrombopoietin supports the continuous growth of cytokine-dependent human leukemia cell lines. Leukemia 11: 541-551.
32. Wernig G, Kharas MG, Okabe R, Moore SA, Leeman DS, et al. (2008) Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 13: 311-320.
33. Kitamura T, Tange T, Terasawa T, Chiba S, Kuwaki T, et al. (1989) Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin. J Cell Physiol 140: 323-334.
34. Quentmeier H, MacLeod RA, Zaborski M, Drexler HG, (2006) JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders. Leukemia 20: 471-476.
35. Howe SJ, Mansour MR, Schwarzwaelder K, Bartholomae C, Hubank M, et al. (2008) Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 118: 3143-3150.
36. Uchiyama T, Kumaki S, Ishikawa Y, Onodera M, Sato M, et al. (2006) Application of HSVtk suicide gene to X-SCID gene therapy: ganciclovir treatment offsets gene corrected X-SCID B cells. Biochem Biophys Res Commun 341: 391-398.
37. Pike-Overzet K, van der Burg M, Wagemaker G, van Dongen JJ, Staal FJ, (2007) New insights and unresolved issues regarding insertional mutagenesis in X-linked SCID gene therapy. Mol Ther 15: 1910-1916.
38. Michiue H, Tomizawa K, Wei FY, Matsushita M, Lu YF, et al. (2005) The NH2 terminus of influenza virus hemagglutinin-2 subunit peptides enhances the antitumor potency of polyarginine-mediated p53 protein transduction. J Biol Chem 280: 8285-8289.
39. Nakase I, Niwa M, Takeuchi T, Sonomura K, Kawabata N, et al. (2004) Cellular uptake of arginine-rich peptides: roles for macropinocytosis and actin rearrangement. Mol Ther 10: 1011-1022.
40. Noguchi H, Matsumoto S, (2006) Protein transduction technology: a novel therapeutic perspective. Acta Med Okayama 60: 1-11.
41. Tyagi M, Rusnati M, Presta M, Giacca M, (2001) Internalization of HIV-1 tat requires cell surface heparan sulfate proteoglycans. J Biol Chem 276: 3254-3261.
42. Lamaziere A, Burlina F, Wolf C, Chassaing G, Trugnan G, et al. (2007) Non-metabolic membrane tubulation and permeability induced by bioactive peptides. PLoS One 2: e201.
43. Baran-Marszak F, Magdoud H, Desterke C, Alvarado A, Roger C, et al. (2010) Expression level and differential JAK2-V617F-binding of the adaptor protein Lnk regulates JAK2-mediated signals in myeloproliferative neoplasms. Blood 116: 5961-5971.
44. Geest CR, Coffer PJ, (2009) MAPK signaling pathways in the regulation of hematopoiesis. J Leukoc Biol 86: 237-250.
45. Mui AL, Wakao H, Kinoshita T, Kitamura T, Miyajima A, (1996) Suppression of interleukin-3-induced gene expression by a C-terminal truncated Stat5: role of Stat5 in proliferation. Embo J 15: 2425-2433.
46. Oh ST, Simonds EF, Jones C, Hale MB, Goltsev Y, et al. (2010) Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood 116: 988-992.
47. Pardanani A, Lasho T, Finke C, Oh ST, Gotlib J, et al. (2010) LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations. Leukemia 24: 1713-1718.
48. Quentmeier H, Geffers R, Jost E, Macleod RA, Nagel S, et al. (2008) SOCS2: inhibitor of JAK2V617F-mediated signal transduction. Leukemia 22: 2169-2175.